A negative genetic test can be valuable information without settling the whole diagnostic question. Its meaning depends on what was tested, which types of change the method could detect and whether the sampled cells contained the change being sought.
Before ordering another test or dismissing a genetic explanation, read the original report’s methods and limitations. The next useful step should address a specific gap.
Three meanings of “we did not find an answer”
| Possible limitation | Question to ask |
|---|---|
| The relevant target was outside the analysis. | Were this gene, region and type of change included? |
| The target was included but difficult to assess. | Was coverage adequate, and what was the validated detection limit? |
| A change was detected but its significance remained uncertain. | What biological or clinical evidence is missing? |
The third situation is different from a missed DNA change. A variant of uncertain significance has been found, but its interpretation is unresolved. MedlinePlus explains the possible meanings of genetic test results. Our ACMG/AMP guide follows the evidence used to classify a variant.
“Highly accurate” needs a defined target
Analytical sensitivity describes how reliably an assay detects a particular change when it is present in the tested sample. Clinical sensitivity concerns how often the test is positive among people with the condition. These are related but different questions: excellent measurement of selected targets cannot identify causes outside the test’s scope.
The distinction is set out in the NHGRI framework for evaluating genetic tests. When a test advertises an accuracy percentage, ask which variants, samples and conditions were used to establish it. Do not assume that performance for single-letter substitutions applies equally to repeat expansions or structural changes.
Example 1: two negative results, different answers
Fictional teaching example. In one family, a specific pathogenic variant associated with inherited cancer risk has already been identified. A relative receives an appropriate test for that exact variant, and it is not found.
In a second family, several people have had cancer, but no causative family variant is known. A broad panel in one person finds no pathogenic variant. That result does not provide the same information as the first family’s targeted result.
NCI distinguishes a true negative for a known family variant from an uninformative negative when the genetic explanation has not been established. Clinical and family history can still matter after testing. See the NCI fact sheet on inherited cancer testing.
The practical question is: “Was the test checking a known explanation, or searching for one?” Keep the relatives’ original laboratory reports available when discussing that distinction; remembered gene names can be incomplete.
Example 2: a gene name on a panel is not a promise about every variant
Fictional teaching example. A panel lists a gene relevant to the patient’s symptoms. Its report describes sequencing of coding regions but says deletion/duplication analysis was not included. The result is negative.
The gene was included, but the report does not establish that every relevant type of change was assessed. The useful follow-up is to ask whether copy-number analysis would address the unresolved question, rather than simply requesting the same sequencing again.
The ACMG technical standard for diagnostic gene panels discusses coverage, copy-number analysis and disclosure of limitations. Actual capabilities differ by laboratory and assay. A method available in one panel should not be assumed to be included in another.
Some mechanisms need particular methods
| Potential gap | Clarification to request |
|---|---|
| Deletion, duplication or another structural change | Which structural variant classes and sizes were validated for this test? |
| Repeat expansion | Was the relevant repeat assessed with a validated method? |
| Methylation or imprinting abnormality | Did testing examine that mechanism, or only the DNA sequence? |
| Highly similar or repetitive sequence | Could the assay distinguish the relevant locus from similar DNA elsewhere? |
GeneReviews’ overview of testing approaches explains why sequencing, copy-number and other methods answer different questions. For a concrete example, FMR1-related disorders require attention to repeat expansion and, where relevant, methylation. A routine sequencing result should not be assumed to have assessed those features.
Likewise, our pseudogene-interference guide explains why very similar DNA sequences can complicate a result. These examples are reasons to check the method, not reasons to assume every broad test has failed.
Example 3: the sample may not contain enough of the change
Fictional teaching example. A genetic change is present in a subset of cells, but the blood sample used for testing contains very few of those cells. The assay reports no variant above its validated detection threshold.
This is a sampling and detection-limit question. More sequencing of the same material does not automatically resolve a change absent from that tissue. Whether another sample is appropriate depends on the suspected condition and the laboratory’s validated approach.
The ACMG standard for next-generation sequencing addresses coverage and detection of mosaicism. Average read depth alone is not enough to establish sensitivity at every position or for every low-level finding.
Reanalysis and a new test are different decisions
Reanalysis revisits existing data with updated knowledge or interpretation. New testing produces additional measurements. Neither automatically replaces the other. Ask which missing information is expected to change and whether it can be recovered from the data already held.
For example, a newly recognized gene–disease relationship may make an existing sequence finding interpretable. A region never adequately measured may instead require another assay. An unresolved splice question may benefit from a suitable RNA investigation; our RNA-sequencing guide explains the importance of tissue and assay context.
A report-reading checklist for the next appointment
- Bring the complete report. Include the test date, sample type and methods, not only the result summary.
- Write the original question. Was the aim diagnosis, a known family variant, carrier testing or something else?
- Identify the remaining gap. Is it scope, measurement, sample choice or interpretation?
- Ask what a proposed next step adds. Which specific gap would it address, and what would remain unresolved?
- Agree on follow-up. Clarify who can request reanalysis and whether the laboratory routinely revisits old data.
Our variant research worksheet can help organize public evidence questions, and the care directory links to professional resources. Neither replaces interpretation of the original report with the clinical team.